Results 81 to 90 of about 14,647 (219)

Periprocedural Management of Patients on Dabigatran Etexilate Treatment [PDF]

American Journal of Neuroradiology, 2011
Dabigatran etexilate is a direct thrombin inhibitor that was initially introduced for oral anticoagulation for the prevention or treatment of venous thrombosis.[1][1] After the recently concluded phase III trial Randomized Evaluation of Long-Term Anticoagulation Therapy,[2][2] dabigatran has ...
Adnan I. Qureshi, Fazeel M. Siddiqui, Masaki Watanabe   +2 more
openaire   +3 more sources

Cerebral Venous Thrombosis and Nitrous Oxide Intoxication: Report of Two Cases and Review of the Literature

Brain and Behavior, Volume 15, Issue 3, March 2025.
This manuscript presents two well‐characterized cases of CVT linked to N2O misuse, managed at a French reference center for rare cerebrovascular diseases. To contextualize our findings, we also provide a narrative review of the existing literature, identifying 10 additional cases of CVT associated with N2O use.
Diana Doukhi, Virginie Siguret, Dominique Vodovar, Maxime Delrue, Peggy Reiner, Agnes Aghetti, Stéphanie Guey, Mikael Mazighi, Isabelle Crassard   +8 more
wiley   +1 more source

Dabigatran etexilate and reduction in serum apolipoprotein B

Heart, 2015
ObjectiveCarboxylesterases, which convert dabigatran etexilate to its active form, dabigatran, have also been shown to influence lipoprotein metabolism, although any pleotropic effects of the drug based on this possible mechanism has not been evaluated.
Jonas Oldgren, John W. Eikelboom, Stuart J. Connolly, Salim Yusuf, Philip Joseph, Jia Wang, Agneta Siegbahn, Paul A. Reilly, Guillaume Paré, Lars Wallentin, Michael D. Ezekowitz, Ellison Themeles   +11 more
openaire   +3 more sources

Dabigatran Etexilate: Future Directions in Anticoagulant Treatment [PDF]

Clinical and Applied Thrombosis/Hemostasis, 2009
Dabigatran etexilate is a novel, oral reversible direct thrombin inhibitor in the clinical development for the treatment and prevention of thromboembolic diseases. Clinical data indicate that dabigatran etexilate has immediate onset of effect, no need for monitoring, predictable and consistent pharmacokinetics and pharmacodynamics—all features that ...
Sam Schulman, Paul A. Reilly
openaire   +2 more sources

Clinical Outcomes of Intracardiac Echocardiography‐Guided Radiofrequency Catheter Ablation for Atrial Fibrillation: A Retrospective Study

Echocardiography, Volume 42, Issue 2, February 2025.
ICE‐guided radiofrequency catheter ablation is safe and effective in the treatment of atrial fibrillation, and it has potential advantages in terms of ablation time, radiation exposure, complication occurrence, and patient prognosis. ABSTRACT Background Routine radiofrequency catheter ablation relies on x‐ray imaging, which may increase the risk of ...
Weiying Long, Qingsong He, Shi Chen, Xue Luo, Wucheng Yang, Jia Zheng, Hua Fu   +6 more
wiley   +1 more source

Thromboembolic recurrence frequency analysis in patients with deep vein thrombosis of lower extremities.

Critical Care Innovations, 2020
INTRODUCTION: To estimate the incidence of thromboembolic recurrence in patients whose deep vein thrombosis (DVT) during the initial and long-term anticoagulation and after its termination was treated.
Sergyi Vasyliuk, Vitaliia Atamaniuk
doaj   +1 more source

Long‐Term Safety and Feasibility of Delayed Left Atrial Appendage Closure After Catheter Ablation

Journal of Interventional Cardiology, Volume 2025, Issue 1, 2025.
Background: This study aimed at comparing the safety and long‐term outcomes pertaining to delayed left atrial appendage closure (LAAC) after catheter ablation (CA). Methods: The retrospective analysis in the study included 474 patients who received LAAC at our center between July 2017 and April 2024.
Ruixue Guo, Yawei Bu, Qiang Zhao, Ruiqin Xie, Jidong Zhang, Irfan Ahmad   +5 more
wiley   +1 more source

Topical issues of the efficiency and safety of using the first direct thrombin inhibitor in real clinical practice

Неврология, нейропсихиатрия, психосоматика, 2016
A Regional Expert Council meeting was held in Moscow on August 21, 2015 to consider different aspects of the efficiency and safety of using the first direct thrombin inhibitor dabigatran etexilate in real clinical practice.
A. V. Fonyakin
doaj   +1 more source

A case of pulmonary vein thrombosis with transient ischemic attacks diagnosed by contrast‐enhanced computed tomography

Respirology Case Reports, Volume 12, Issue 12, December 2024.
Pulmonary vein thrombosis (PVT) is rarer than pulmonary artery thrombosis (PAT). The diagnosis of PVT is often difficult due to its nonspecific symptoms, such as cough, hemoptysis, and dyspnea, and can be missed if the clinician does not suspect it.
Yoshimasa Ogata, Keisuke Aita, Juri Maeda, Risa Shiragami, Masaaki Hagiya, Kiyohiko Shuto, Fumitaka Nakamura, Masao Yamaguchi   +7 more
wiley   +1 more source

Promising areas of research on the pharmacogenetics of dabigatran etexilate

Pharmacogenetics and Pharmacogenomics, 2020
Dabigatran etexilate is a prodrug of dabigatran, a direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists.
A. Savinova, N. Shnayder, M. Petrova, R. Nasyrova   +3 more
semanticscholar   +1 more source